Quick Answer
Aclaris Therapeutics, Inc. reported Diluted EPS of $0.53 per share (loss) for fiscal year 2025.
Aclaris Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.53 | +69.0% |
| 2024 | -$1.71 | -34.6% |
| 2023 | -$1.27 | +4.5% |
| 2022 | -$1.33 | +16.9% |
| 2021 | -$1.60 | -33.3% |
| 2020 | -$1.20 | +69.2% |
| 2019 | -$3.90 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | -9.1% | +7.7% |
| June 30, 2025 | -$0.13 | +13.3% | -8.3% |
| March 31, 2025 | -$0.12 | +50.0% | -9.1% |
| September 30, 2024 | -$0.11 | +73.2% | +26.7% |
| June 30, 2024 | -$0.15 | +64.3% | +37.5% |
| March 31, 2024 | -$0.24 | +42.9% | +41.5% |
| September 30, 2023 | -$0.41 | -36.7% | +2.4% |
| June 30, 2023 | -$0.42 | -35.5% | +0.0% |
- Aclaris Therapeutics, Inc. showed an increase of +69.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Aclaris Therapeutics, Inc.’s diluted eps has grown by 86.4% (from $3.90 per share (loss) to $0.53 per share (loss)).
- The most recent figure is from Aclaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: